FEBRUARY 18, 2012

Browse Categories

Beyond the Abstract - Pathological Evidence of Necrosis in Recurrent Renal Mass Following Treatment with Sunitinib

Tue, 22 January 2008
E-mail Print

BERKELEY, CA (UroToday.com) - Sunitinib is a highly potent, selective inhibitor of certain protein tyrosine kinases, including VEGF-R types 1 to 3, PDGF-R- , and PDGF-R-ß.




Your session will expire in 8 hours requiring you to log in each day to view content.
Share |